Board of Directors

Peter G. Savas
Chairman & Chief Executive Officer: Mr. Savas has served as Chairman and Chief Executive Officer of Alseres Pharmaceuticals, Inc. since September 2004. Prior to joining ALSE, Mr. Savas was Chairman, President and Chief Executive Officer of Aderis Pharmaceuticals, a privately held biopharmaceutical company headquartered in Hopkinton, MA. He undertook and completed a $45 million private placement at nearly double the valuation of the prior venture round, strengthened the Board of Directors, Scientific Advisory Board and management, culled out dead-end programs and revitalized and expanded corporate partnerships. Before joining Aderis, Mr. Savas was Chairman, President, and CEO of Unisyn Technologies, a company he refinanced, repositioned and subsequently merged with Cellex Biosciences. Before Unisyn, Mr. Savas served as Senior Vice President of Zymark Corporation, a laboratory automation company; Chairman, President and CEO of Xydex Corporation, a company he founded to in-license, develop, and commercialize novel separations technology which he subsequently sold to Genex Corporation. He was also Vice President and General Manager of Business Operations of the Continental Water Systems and the Waters Associates Divisions of Millipore Corporation. He serves on the Board of Directors of Sivida Corporation. Mr. Savas earned his BA in chemistry from Syracuse University.
Henry Brem M.D.
Director: Henry Brem, M.D. joined the Board of Directors in February 2007. Dr. Brem has been a professor at Johns Hopkins University School of Medicine since 1984. He serves as the Director of the Department of Neurosurgery, Harvey Cushing Professor of Neurosurgery, Professor of Ophthalmology, and Oncology. He is also Director of the Hunterian Neurosurgical Research Laboratory. Dr. Brem obtained his bachelor's degree from NYU and received his medical degree from Harvard Medical School. He trained in surgery at the Peter Bent Brigham Hospital in Boston and in neurosurgery at the Neurological Institute of New York at Columbia University. Brem has authored more than 150 articles in scientific journals. He is responsible for developing Gliadel® wafer, a brain cancer treatment, from concept through FDA approval. Dr. Brem holds several patents for therapeutic agents and delivery methods.
Member of the Science and Technology Committee
Gary Frashier
Directors: Gary Frashier joined the Board of Directors in February 2007. Mr. Frashier, through his company Management Associates, has been a strategic consultant to emerging growth companies in the life sciences field for the last five years. From 1990 until September 1998, he served as Chief Executive Officer of OSI Pharmaceuticals, Inc., a biotechnology company, and, from January 1997 until September 2000, as its Chairman of the Board. From 1987 until 1990, he served as President and CEO of Genex Corporation, a protein engineering company, and from 1984 until 1987, as Chairman and CEO of Continental Water Systems, Inc., a manufacturer and marketer of equipment to produce high purity water used by the pharmaceutical, medical, electronics and research industries. Mr. Frashier also served as Executive Vice President of Millipore Corporation, a provider of products and services to biopharmaceutical, manufacturing, clinical, analytical and research laboratories, and President of Millipore's Waters Associates subsidiary. Mr. Frashier serves on the Board of Directors of Apex BioVentures Acquisition Corporation; TeKMira Pharmaceuticals Corporation; and Achillion Pharmaceuticals Inc. Mr. Frashier has a B.S in Chemical Engineering from Texas Tech University and received his M.B.A. from the Massachusetts Institute of Technology.
Chair of the Nominating and Governance Committee
Member of the Compensation Committee
Member of the Science and Technology Committee
William L.S. Guinness
Directors: William Guinness joined the Board of Directors in July 2006. Mr. Guinness has been Chairman of Sibir Energy plc since 1999 and had additional roles with Pentex Energy plc and Pentex Oil plc. Mr. Guinness has been involved with various private venture capital operations, which cover areas as diverse as metal manufacturing, general aviation, and fine art consultancy. Mr. Guinness is also a director of a number of private companies involved in a wide range of commercial activities. Mr. Guinness previously served on the Company's Board of Directors from June 30, 2003 to September 20, 2003.
Member of the Audit Committee
Robert Langer Sc.D.
Director: Dr. Langer has been a member of the Board since June 2000. Dr. Langer is one of 14 Institute Professors (the highest rank awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). He received a Bachelor's Degree from Cornell University in 1970 and a Sc.D. from MIT in 1974, both in chemical engineering. Dr. Langer has received honorary doctorates from the ETH (Switzerland) and the Technion (Israel). Dr. Langer has written more than 800 articles, 400 abstracts, 500 patents (one of which was cited as the outstanding patent in Massachusetts in 1988 and one of 20 outstanding patents in the U.S.), has given more than 600 invited lectures (50 named lectureships), and has edited 13 books. Dr. Langer has received over 130 major awards. He is the only engineer to receive the Gairdner Foundation International Award (56 recipients of this award have subsequently received a Nobel Prize), and he received the Lemelson-MIT Prize, the world's largest prize for invention. He is also the recipient of the Charles Stark Draper Prize, the world's highest engineering prize, from the National Academy of Engineering. In 1989, Dr. Langer was elected to the Institute of Medicine and the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. Dr. Langer serves on the Boards of Directors of Momenta, Pharmaceuticals, Inc; EchoTherapeutics; and Wyeth.
Member of the Nominating and Governance Committee
Chair of the Science and Technology Committee
Michael J. Mullen CPA
Director: Mr. Mullen has been a member of the Board since June 2004. Mr. Mullen is currently the Chief Financial Officer of Magellan Biosciences, Inc., a clinical diagnostics company. From February 2003 to March 2006, Mr. Mullen was the Chief Financial Officer of JMH Capital, a private equity firm. From September 2000 to December 2002, Mr. Mullen was the Chief Financial Officer of Magellan Discovery Technologies, a private equity sponsored buyout firm. From March 1999 to September 2000, Mr. Mullen was the Chief Financial Officer and Director of Integration for the Analytical Instrument Strategic Business Unit of PerkinElmer, Inc., a provider of scientific instruments, consumables and services. From December 1995 to March 1999, Mr. Mullen was the Controller of Thermo Optek, a publicly traded subsidiary of Thermo Electron and manufacturer of spectroscopy instrumentation for molecular and elemental analysis. Mr. Mullen received his B.B.A from James Madison University.
Chair of the Audit Committee
Member of the Nominating and Governance Committee
Member of the Compensation Committee
John T. Preston
Director: Mr. Preston has been a member of the Board since June 2004. Mr. Preston is President and Chief Executive Officer of Atomic Ordered Materials LLC and Senior Lecturer at the Massachusetts Institute of Technology ("MIT"). From 1992 through 1995, Mr. Preston served as Director of Technology Department at MIT. From 1986 to 1992, Mr. Preston was the Director of the MIT Technology Licensing Office where he was responsible for the commercialization of intellectual property developed at MIT. Some of Mr. Preston's prior appointments include director or advisory positions for the Governor of Massachusetts, The U.S. Department of Defense, The National Aeronautics and Space Administration and the Technology Board of Singapore. Mr. Preston holds an MBA from Northwestern University and a BS in Physics from the University of Wisconsin. Mr. Preston is also a member of the Board of Directors of Clean Harbors, Inc. and is also a member of the Board of Directors of several private companies.
Member of the Audit Committee
Chair of the Nominating and Governance Committee
Member of the Compensation Committee